Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in HFpEF (SATELLITE)
NCT03756285Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF), sponsored by AstraZeneca. Started Dec 2018; status: terminated.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT03756285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756285.